Cells remove unstable polypeptides through protein quality control pathways including ubiquitin mediated proteolysis and autophagy. We investigated how these pathways are utilized in β-thalassemia, a common hemoglobinopathy in which β globin gene mutations cause accumulation and precipitation of cytotoxic α globin subunits. In β-thalassemic erythrocyte precursors, free α globin was polyubiquitinated and degraded by the proteasome. These cells exhibited enhanced proteasome activity and transcriptional profiling revealed coordinated induction of most proteasome subunits, mediated by the stress response transcription factor Nrf1.
INTRODUCTION:
Production of functional hemoglobin (Hb) A tetramers (α 2 β 2 ) requires the coordinated synthesis and assembly of α and β globin protein chains and iron-containing heme groups.
Individually, all HbA components are toxic to red blood cells (RBCs) and their precursors. This is illustrated by the β-thalassemias, a common hemoglobinopathy in which β globin gene (HBB) mutations cause buildup of free α globin.
1 These unpaired α chains initiate an oxidative damage cascade and form damaging precipitates that contribute largely to the clinical problems of β-thalassemia.
The pathophysiology of β-thalassemia bears similarities to a diverse group of protein aggregation diseases affecting multiple organs (reviewed in 2 ). These disorders, which include
Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and α 1 -antitrypsin deficiency, are caused by accumulation of unstable, relatively insoluble proteins. It is believed that affected cells can detoxify and remove these damaging proteins via multiple interacting biochemical pathways termed protein quality control (PQC), but that disease ensues when compensatory mechanisms are overwhelmed (reviewed in [3] [4] [5] ). Cellular PQC systems include molecular chaperones, ubiquitin mediated proteolysis, and autophagy. Several lines of evidence suggest that β-thalassemic erythroid cells utilize PQC pathways to detoxify free α globin (reviewed in 2 ). First, the clinical severity of β-thalassemia is proportional to the degree of α globin excess. Second, there is a threshold below which excess α globin is less harmful, as illustrated by subjects with β-thalassemia trait, who experience 50% reduced β globin synthesis
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Numerous studies indicate that normal and β-thalassemic erythroid precursors can balance globin ratios through selective α chain proteolysis. Pulse-chase experiments using intact human β-thalassemic erythroid cells [6] [7] [8] [9] [10] [11] [12] [13] and cell lysates 11, 13, 14 showed that excessive α chains are actively degraded and accumulate mainly in late stages of erythroid maturation, presumably as proteolytic capacity becomes exceeded. The ubiquitin proteasome system (UPS) (reviewed in 3 ), originally characterized in reticulocyte lysates using denatured hemoglobin as a substrate, 15 is responsible for physiological degradation of native proteins and for removing misfolded proteins as part of PQC in all cells. Studies by Shaeffer and colleagues showed that normal and β-thalassemic hemolysates can ubiquitinate and degrade exogenous α globin, 12, 14 although the associated pathways remain largely uncharacterized. RBC precursors also employ autophagy, a group of related processes in which targeted proteins or organelles are fused to lysosomes and degraded. 16 For example, autophagy-related genes are upregulated by the master erythroid transcription factor GATA-1 during terminal erythropoiesis. 17 During reticulocyte maturation, mitochondria are eliminated by "macroautophagy" (reviewed in 4, 16 ), a process in which cells form double membrane vesicles (autophagosomes) around cytoplasmic contents for delivery to lysosomes. [18] [19] [20] Interestingly, electron micrographs of β-thalassemic erythroblasts identify a subset of α globin precipitates within lysosomes. 2, 21, 22 More recent work indicates that autophagic processes are increased in HbE/β-thalassemia.
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For personal use only. on December 30, 2017. by guest www.bloodjournal.org From Most studies linking PQC to detoxification of free α globin in β-thalassemia were performed prior to the development of newer genetic and pharmacological approaches to interrogate the relevant mechanisms. Moreover, recent proof-of-principle studies have shown that induction of PQC can improve phenotypes of various aggregation disorders in murine models. For example, pharmacological activation of autophagy can attenuate liver damage in α 1 -antitrypsin deficiency, 24 and genetic upregulation of proteasome activity can alleviate proteotoxic heart disease. 25 Before such principles can be applied to β-thalassemia, the relevance and contributions of PQC pathways involved in neutralizing free α globin must be better defined.
We investigated this problem in a mouse model of β-thalassemia and in human patient cells. We demonstrate that the UPS, autophagy and heat shock responses all likely participate in the detoxification of free α globin and that these pathways are coordinately regulated. 
Human samples
Blood samples were collected from β-thalassemia patients (pre-transfusion reticulocyte counts of 3-10%) and control subjects at the Children's Hospital of Philadelphia per research protocols approved by the local Institutional Review Board. Written informed consent was obtained from all participants.
Isolation and analysis of insoluble globin fractions
Analysis of globin precipitates in circulating erythrocyte membrane skeletons was performed as described. 27 For fetal liver cultures, cells were lysed in RIPA buffer containing 1 mM DTT, 1 mM PMSF, and protease inhibitor cocktail (Sigma 
Reticulocyte pulse-chase analysis
Freshly collected mouse erythrocytes and reticulocytes were used for pulse-chase experiments with 35 S-labeled methionine and cysteine (PerkinElmer), 27 as described in supplemental methods. When indicated, chase medium contained 100 μM chloroquine (Sigma), 0.5 μM epoxomicin, 10 μM MG132 (Enzo Life Sciences) or 0.1% DMSO as control.
Fetal liver cultures
Fetal livers were collected from E14.5 embryos from crosses of wild type or Th3/+ x Th3/+ mice. Embryos were genotyped and erythroid precursors were isolated from individual embryos using EasySep hematopoietic progenitor enrichment kit (StemCell Technologies) supplemented with biotin-conjugated CD71 antibody (Biolegend). Purified CD71 -Lin -cells were cultured in differentiation medium consisting of IMDM with 10% FCS, 10% PDS, 2 mM Lglutamine, 10 μM 1-thioglycerol, 1% Penicillin/streptomycin, 5% PFHM-II medium, and 5 U/mL erythropoietin (Amgen). For retroviral infections, cells were cultured in expansion medium consisting of StemPro34 medium (Invitrogen) supplemented with 2 mM L-glutamine, 1% Penicillin/streptomycin, 10 μM 1-thioglycerol, 1 μM dexamethasone, 0.5 U/mL erythropoietin, and 1% murine SCF conditioned medium. 28 After 72 hours of expansion, cells were washed and resuspended in differentiation medium. For Nrf1 and Nrf2 induction experiments, cells in differentiation medium were treated for 24 hours with 0.1 μM MG132 or 1 μM R-sulforaphane (LKT laboratories). For proteasome inhibition studies, cells were incubated for 12 hours with 1 or 10 μM MG132 as indicated. 
Bortezomib treatment and hematological analysis
Mice were treated by intraperitoneal injection of 0.25 mg/kg, 0.5 mg/kg, or 1.0 mg/kg bortezomib (Velcade, Millenium Pharmaceuticals) in normal saline, or with saline control, every 3 days. Blood was collected by submandibular bleeding, anticoagulated with EDTA, and analyzed on a Hemavet HV950FS analyzer (Drew Scientific). Reticulocyte counts were done using Retic-COUNT reagent (BD Biosciences). Bone marrow erythroid precursors were purified from mice using the EasySep PE Selection Kit (StemCell Technologies), with Ter119-PE antibody (Biolegend).
Real-time RT-PCR
Quantitative real-time PCR was done using the standard curve method using SYBR green dye on an ABI 7900 real-time machine (PE Applied Biosystems). Target gene expression was normalized to the average of Actb and Hprt values. For proteasome subunit PCR, multiple randomly selected subunits were examined as indicated, and the average fold change is presented.
Primer sequences are described in supplemental methods.
Statistical methods
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Statistical analysis was performed using GraphPad Prism 4.0 software (Graphpad Software). All multi-group comparisons were done using one-way ANOVA analysis.
Comparisons between two groups were done using Student's t-test.
RESULTS
Insoluble α globin accumulates in proteasome-inhibited β-thalassemic reticulocytes.
We investigated whether pharmacological inhibition of the UPS impairs α globin turnover and accumulation in β-thalassemic erythroid cells. We used Th3 mutant mice, in which both the β1 (Hbb1) and β2 (Hbb2) adult globin genes are deleted. 26 Homozygous mutants (Th3/Th3) die in utero or perinatally of severe anemia. Heterozygous animals (Th3/+) are viable and exhibit microcytic hypochromic anemia with accumulation of insoluble α globin chains in erythroid precursors and in the membranes of circulating erythrocytes ( Figure 1A ). In general, the extent of α globin precipitation within the latter reflects the severity of β-thalassemia and can be used as a surrogate marker to gauge disease modifiers.
27,30,31
Pulse radiolabeling, followed by chase with unlabeled amino acids, demonstrates that insoluble α globin is degraded with a half-life of about 2 hours in murine Th3/+ reticulocytes ( Figure 1B and 1C) . Similar degradation of membrane-associated insoluble α globin has been observed in human samples. 12, 13 Treatment with two different proteasome inhibitors, MG132 and epoxomicin, during the chase period decreased the turnover of α globin aggregates, indicating that α globin is degraded at least partly by ubiquitin-mediated proteolysis. (Figure 1B and 1C).
To study α globin degradation further, we used a mouse fetal liver erythroid culture system in which purified erythroid progenitors mature synchronously over 72 hours. 32 In this system, cultured murine Th3/Th3 cells accumulate insoluble α globin and begin to die at about 36-48 hours of differentiation, while the Th3/+ cells mature at a slightly delayed rate relative to wild type cells. Remarkably, after 48 hours of culture, Th3/+ erythroblasts contain relatively little insoluble α globin compared to Th3/Th3 cells ( Figure 1D ), consistent with the presence of compensatory proteolytic mechanisms as observed in human thalassemic erythroblasts. 7, 9, 12 Treatment with MG132 caused dose dependent accumulation of insoluble α globin chains in Th3/+ cultured erythroblasts and to a lesser extent, in control cells ( Figure 1E , top two panels).
The latter finding suggests that the UPS may degrade the free α chains that are synthesized at slight excess relative to β chains during normal erythropoiesis. 33 SQSTM1/p62, which serves as a marker of insoluble protein aggregates in structures termed aggresomes 34 (see Discussion), also co-purified with this fraction after proteasome inhibition in wild type and Th3/+ cells. We performed gene set enrichment analysis (GSEA) to assess whether transcripts that are differentially expressed in β-thalassemia are enriched for specific biological properties or functions. 35 The most highly enriched gene set in both Th3/+ and Th3/Th3 erythroblasts was the proteasome pathway ( Figure 3A ), which was overrepresented in β−thalassemia at high statistical significance (normalized enrichment scores of 2.44 (Th3/+) and 2.11 (Th3/Th3), with false discovery rate q-values less than 0.0001). Messenger RNAs encoding all subunits of the catalytically active 20S proteasome complex, and almost all subunits of the regulatory 19S complex, were upregulated in an α globin-dosage dependent manner ( Figure 3B ). The β subunits specific for the immunoproteasome, which is involved in generation of peptides for MHC display, were not altered. We used MV151, a fluorescent proteasome inhibitor that binds specifically to active proteasome subunits, 29 to determine whether proteasome activity is enhanced in β-thalassemic cells ( Figure 3C ). Figure 3B . We were not able to examine Th3/Th3 cultures due to high toxicity of MV151 in these cells.
We also used MV151 to analyze proteasome activity in circulating reticulocytes from human β-thalassemia major patients. Human thalassemic patient reticulocytes also had increased proteasome activity relative to reticulocytes from healthy controls ( Figure 3E ).
Together, these data indicate that upregulation of proteasome subunit transcripts in β-thalassemia leads to production of new functional proteasomes.
Transcription factor Nrf1 induces proteasome subunit mRNAs in normal and β-thalassemic erythroblasts
Proteasome subunit genes contain antioxidant response elements (AREs) that are bound 39 induced the Nrf2-specific target gene Nqo1 ( Figure 4A ), but had no effect on proteasome subunit mRNAs ( Figure 4B ). In contrast, treatment with low-dose (0. 
. 40 Incubation at 42 o C for one hour to induce heat shock increased Hsp105 transcripts ( Figure   4G ), but failed to upregulate proteasome subunits ( Figure 4C ). Therefore, induction of proteasome subunits by proteasome inhibition is independent of heat shock responses.
Next, we investigated whether proteasome subunit mRNA upregulation in β 
In vivo proteasome inhibition impairs erythropoiesis in wild type and β-thalassemic mice
To determine the in vivo importance of the UPS in modulating α globin toxicity, we treated β-thalassemic mice with the proteasome inhibitor bortezomib. 41 Proteasome inhibition is potentially toxic to all cells and has been shown to impair normal erythroid differentiation in vitro. 42 However, we reasoned that if β-thalassemic erythroblasts are dependent on the UPS for degradation of excess α globin, then affected mice may exhibit increased bortezomib-induced toxicities compared to wild type animals. We first confirmed that bortezomib can impair α globin turnover ex vivo in Th3/+ mouse reticulocyte pulse-chase experiments (Supplemental Figure 3) . We then carried out a dose-escalation trial in which wild type or Th3/+ mice were treated with bortezomib at doses similar to those used in human patients ( Figure 5A ). 43 The timing of treatment at each dose was 2-3 weeks, which represents approximately one half-life for wild type murine RBCs. Examination of circulating RBCs at 24 hours after systemic treatment with bortezomib revealed ~25% inhibition of proteasome activity at 0.25 mg/kg and ~30-40% inhibition at 1.0 mg/kg ( Figure 5B ), consistent with previous reports. 44 Lower doses of drug (0.25 mg/kg and 0.5 mg/kg), produced minimal effects on RBC parameters (Supplemental Table   1 ). At 1.0 mg/kg bortezomib, RBC counts and hemoglobin decreased by similar extents in both wild type and Th3/+ mice (Supplemental Table 2 and Figures 5C and 5D ). Similar results were also obtained with 3-week treatment at 1.0 mg/kg without dose escalation (data not shown).
Bortezomib treatment caused an increase in spleen size ( Figure 5E ) and expansion of early erythroid precursors in the bone marrow and spleen of both wild type and Th3/+ mice, although the effects were more prominent in wild type animals (Supplemental Figure 4) . 31,32 Importantly, bortezomib did not alter turnover of insoluble α globin in (Th3/+) reticulocytes or increase the levels of insoluble globins in wild type or Th3/+ RBCs (Figure 5F and 5G). Overall, UPS
inhibition by bortezomib generally impaired erythropoiesis with subtle differences in drug effects on wild type versus Th3/+ mice. However, bortezomib did not cause accumulation of α globin precipitates or enhanced toxicity in the β-thalassemic animals.
Systemic proteasome inhibition activates alternate protein quality control pathways
The failure of bortezomib to enhance α globin accumulation in β-thalassemic mice contrasts with our findings that proteasome inhibition blocks degradation of free α globin in erythroid cultures and in reticulocytes. In vivo, early-stage erythroid progenitors may activate alternate PQC pathways in response to systemic proteasome inhibition. To investigate this, we analyzed purified Ter119 + erythroid precursors from bone marrow of bortezomib-treated wild type and Th3/+ mice. Proteasome inhibition activates Heat Shock Factor (HSF) transcription factors that induce the expression of heat shock proteins (HSPs), molecular chaperones that bind misfolded proteins to stabilize their structures and prevent precipitation. 40 In wild type fetal liver erythroblasts, proteasome inhibition induced mRNAs encoding Hsp105 ( Figure 4G ) and Hsp90aa1 (not shown). Without bortezomib treatment, numerous HSP mRNAs trended toward upregulation in Th3/+ erythroblasts, likely reflecting proteotoxic stress and activation of the HSF pathway ( Figure 6A ). However, a significantly greater HSP response resulted from systemic treatment with bortezomib in both wild type and Th3/+ erythroid precursors. Thus, one compensatory response to proteasome inhibition is induction of HSPs, which may alleviate some toxic effects of free α globin in β-thalassemia.
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Autophagy is active during normal erythropoiesis 17 and has been shown to degrade unstable proteins in numerous diseases. 5 We investigated whether autophagy compensates for proteasome inhibition during normal and thalassemic erythropoiesis. We used Western blotting to examine the autophagosome marker LC3b in purified Ter119 + bone marrow cells ( Figure 6B ).
LC3b levels, including the phosphatidylethanolamine-conjugated (type II) form indicative of active autophagy, were increased in Th3/+ erythroblasts compared to wild type, similar to what was reported for human thalassemic cells. 23 Systemic bortezomib treatment increased LC3b in both genotypes. Thus, the highest levels of autophagy were observed in Th3/+ mice treated with the proteasome inhibitor. Next, we investigated whether autophagy participates in turnover of α globin aggregates in β-thalassemia. In pulse-chase studies of Th3/+ mouse reticulocytes, ATP depletion (which inhibits both the UPS and autophagy) reduced degradation of α globin aggregates to a greater extent than proteasome inhibition alone (Supplemental Figure 5) .
Inhibition of lysosomal acidification with chloroquine inhibited α globin degradation to a similar extent as proteasome inhibition, while both inhibitors together produced additive effects ( Figure   6C and 6D). Together, our results indicate that in β−thalassemia, excess α globin is degraded by autophagy and that this process is enhanced upon inhibition of the UPS. Thus, both HSP and autophagy pathways are induced by bortezomib in wild type and Th3/+ mice. Induction of these PQC components likely explains why systemic proteasome inhibition does not enhance the accumulation of precipitated α globin in Th3/+ mice.
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DISCUSSION:
More than 40 years ago, Fessas, Bank, Nathan, Weatherall and others demonstrated that β-thalassemia is caused by globin chain imbalance and that accumulation of cytotoxic free α globin is a primary determinant of disease pathophysiology. [45] [46] [47] [48] Additional early studies, interpreted in light of more recent work, indicate striking similarities between β-thalassemia and a class of diseases termed "protein aggregation disorders" (reviewed in 2 ). Previous studies have shown that free α chains can be ubiquitinated in cell-free systems or in reticulocyte lysates in vitro 14 and that ATP-dependent degradation of α chains occurs in β-thalassemic patient reticulocytes. 12 We used a mouse model of β-thalassemia to establish a simple system for following the fate of excess α globin in live cells. We show that newly synthesized excess α globin chains rapidly associate with an insoluble stromal fraction and are degraded, mirroring earlier findings in human cells. 12 Both proteasomal and lysosomal inhibitors alter turnover of insoluble α chains, implicating the UPS and autophagy in this process. Most likely, autophagy mediates direct turnover of insoluble α globin, while the UPS degrades soluble α globin, which accumulates and shifts to the insoluble fraction after proteasome inhibition in isolated reticulocytes. This interpretation of the current data is consistent with electron microscopy analysis of human β-thalassemic erythroblasts, where putative electron-dense α globin inclusions were observed being engulfed by and within lysosomes. 21, 22 In addition, our denaturing immunoprecipitation experiments detect insoluble polyubiquitinated α globin chains in β-thalassemic erythrocytes, even without proteasome inhibitor treatment. These findings show for the first time that free α globin is polyubiquitinated in vivo and suggest that the form of α globin recognized by ubiquitin ligases is misfolded and/or unstable. Most likely, a proportion of polyubiquitinated α globin precipitates in β-thalassemic erythroblasts because proteasomal degradation systems are saturated.
Our study indicates that in β-thalassemia, unstable α globin does not form static precipitates, but rather, exists in dynamic subcellular fractions that interact with both UPS and autophagy pathways. These features raise the possibility that free α globin interacts physically with the aggresome, a recently described intracellular structure where unstable proteins colocalize with PQC machinery, specialized adapter proteins, and cytoskeleton. 49 In support, 51, 52 Mice lacking Nrf1 in neurons exhibit reduced brain proteasome activity and neurodegeneration. 53 Global deletion of Nrf1 leads to embryonic lethality from anemia, but this defect is not cell autonomous, so the role of Nrf1 in erythroid development, and in proteasome function therein, remains unknown. 54 We used drugs and shRNAs to show that Nrf1 mediates erythroid proteasome upregulation in β-thalassemia. TCF11, the human isoform of Nrf1 shown to activate proteasome subunit gene transcription, is normally constitutively degraded via the proteasome. 38 Thus, proteasome inhibition stabilizes TCF11, which translocates to the nucleus and activates transcription via AREs. Mechanistically, this likely occurs through proteotoxic stress and proteasome "clogging" by aggregated α subunits in β-thalassemia. Pharmacologic upregulation of Nrf1 activity may be a potential route to further increase proteasome activity in thalassemic mice and patients in future studies.
Systemic bortezomib impaired erythropoiesis in a dose-dependent fashion, consistent with in vivo studies of proteasome inhibition 42 and reports of anemia as a drug toxicity in patients. 55 Contrary to our initial expectations, bortezomib did not produce a disproportionately adverse effect or enhance α globin accumulation in β-thalassemic mice. This may be explained by our observations that multiple erythroid PQC pathways are activated additively by β-thalassemia and systemic protease inhibition. These induced pathways include an HSP response, which produces molecular chaperone proteins that bind denatured "client" proteins to either promote their refolding, or target them for degradation (reviewed in 56 ). Additionally, thalassemia and bortezomib additively induced the autophagosome marker LC3b, suggesting increased autophagic flux. Moreover, free α globin is degraded by autophagy in thalassemic reticulocytes (see Figure 6 ). Our findings are consistent with the concept that PQC pathways are interrelated and interactive. Proteasome inhibition induces both HSPs 40 and macroautophagy 57, 58 by causing the accumulation of denatured proteins, which activate various cellular unfolded protein responses. These compensatory pathways are more likely to be induced in vivo in early stage erythroid precursors during the relatively long time course of systemic bortezomib administration, compared to brief ex vivo protease inhibitor treatment of isolated late-stage fetal liver erythroblasts or transcriptionally inert reticulocytes. In the future, it will be of interest to investigate how in vivo suppression of autophagy affects β-thalassemia. Use of lysosomal inhibitors, such as chloroquine, is complicated by the potential for autophagy-independent effects, such as interference with iron metabolism, which would impair erythropoiesis. Most likely, erythroid-specific suppression of autophagy pathways via genetic manipulation in mice will be the best initial approach to investigate whether β-thalassemia is sensitive to the loss of this pathway, with or without proteasome inhibition.
Together, our data indicate that β-thalassemic erythroid cells compensate for α globin excess through multiple, functionally interconnected PQC pathways and that decreased flux through a single pathway can be compensated for by enhanced activity of the others. Up to a certain threshold level, combined PQC pathways can detoxify most excess α globin to minimize clinical phenotypes. Our studies indicate that β-thalassemia, and potentially other hemoglobinopathies, can be studied using the same tools and models currently being applied to a broad range of protein aggregation disorders. Given the high degree of clinical variability in β-thalassemic patients, some of which cannot be explained by β globin gene mutations or
expression, it may be informative to examine genetic variation of PQC pathways in these patients. Moreover, improved understanding of how erythroblasts modulate PQC components in response to accumulation of free α globin may illustrate new pharmacologic and genetic means to upregulate the activity of these pathways for treating β-thalassemia and other protein aggregation disorders affecting non-erythroid tissues.
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